Compare Vanguard Growth Index Fund ETF (VUG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Growth Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Growth Index Fund ETF trades at $86.09, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VUG | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $90.29 | $167.51 |
52-Week Low | $70.00 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUG trades at $85.32, up 0.06% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The ETF's growth-focused strategy, concentrated in large-cap U.S. companies, benefits from a low expense ratio of 0.03% and a decade-long track record of strong returns, though key financial ratios are not disclosed in the provided data. Recent news highlights its appeal for long-term investors seeking exposure to growth stocks.
The outlook for VUG is mixed, with technical weakness offset by positive sentiment for long-term growth potential. Risks include high tech concentration and market volatility, but analyst coverage emphasizes its cost efficiency and diversification benefits for buy-and-hold strategies.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
